- Olsen and colleagues randomised 393 men aged 18 to 49 to 5% minoxidil, 2% minoxidil or placebo for 48 weeks, and 5% was superior to both.
- Minoxidil is a licensed medicine, and a 2022 network meta-analysis (Gupta et al., JAMA Dermatology) supports its efficacy.
- RU-58841 was developed by Roussel-Uclaf in the 1980s and shelved in the 1990s before any human trial completed.
- Battmann et al. (1994, PMID 8136306) reported local antiandrogen effects in hamsters with no change in prostate weight or testosterone.
- Pan and Uno (1998, PMID 9798729) reported increased hair density, thickness and length in stump-tailed macaques.
- No published study has compared RU-58841 and minoxidil directly.
- Minoxidil and RU-58841 are not competitors on the same pathway. Minoxidil is a licensed growth stimulant that works through potassium channels and the hair cycle. RU-58841 is an unlicensed androgen receptor antagonist that blocks DHT signalling where it is applied.
- Minoxidil has randomised placebo-controlled trials in hundreds of men and a 2022 network meta-analysis behind it. RU-58841 has 1990s animal studies and no completed human trial.
- No study has ever compared the two directly. Any claim that one "beats" the other is opinion, not data.
The short answer
The question "RU58841 vs minoxidil" assumes the two sit in the same category. They do not. Minoxidil is a growth stimulant that is indifferent to androgens. RU-58841 is an antiandrogen that does nothing to stimulate growth directly; it blocks the signal that shrinks follicles. Minoxidil is a licensed pharmacy medicine in the UK with four decades of trial data. RU-58841 was developed by Roussel-Uclaf in the 1980s, shelved in the 1990s before any human trial completed, and today exists only as a research compound. The comparison is really between a proven medicine and a plausible but untested molecule.
How minoxidil works
Minoxidil began life as an oral blood-pressure drug and was reformulated for the scalp after patients noticed hair growth. On the scalp it is converted by sulphotransferase enzymes to minoxidil sulphate, the active form. Messenger and Rundegren's 2004 review in the British Journal of Dermatology summarises the evidence: the drug appears to shorten telogen, prolong anagen and enlarge miniaturised follicles, with potassium channel opening the best-supported mechanism and the full picture still incomplete [1]. Note what is not on that list: androgens. Minoxidil does not lower DHT and does not touch the androgen receptor. It is not a DHT blocker, whatever the marketing on some bottles says.
How RU-58841 works
RU-58841 is a nonsteroidal androgen receptor (AR) antagonist from the same hydantoin family as nilutamide. Battmann and colleagues at Roussel-Uclaf reported in 1994 that it binds the AR with high affinity and, applied topically in hamsters, produced strong local antiandrogen effects at doses that left the prostate and testosterone levels unchanged [2]. Pan and co-workers later showed in cell assays that it suppresses DHT activation of the receptor with potency comparable to hydroxyflutamide [3]. In pattern hair loss, DHT bound to the AR drives the gene programme that miniaturises follicles. An antagonist in the receptor means DHT cannot dock, so the signal stops at the point of application. For a fuller treatment see What is RU58841?
The evidence gap, side by side
This is the part of the comparison that matters most and that most vendor pages skip.
Minoxidil: human trials, decades of them
Olsen and colleagues randomised 393 men aged 18 to 49 with androgenetic alopecia to 5% minoxidil, 2% minoxidil or placebo, twice daily, for 48 weeks. The 5% solution was significantly superior to both 2% and placebo on non-vellus hair counts, patient ratings and investigator ratings, with about 45% more regrowth than 2% at week 48 [4]. That is a single well-run trial among many. In 2022 Gupta and colleagues published a network meta-analysis in JAMA Dermatology pooling 23 randomised trials of minoxidil, finasteride and dutasteride in men, which placed topical minoxidil as an effective option, below oral dutasteride and finasteride on 24-week hair count gain [5]. Minoxidil's weaknesses are also well characterised: a substantial fraction of users respond poorly, local irritation is common with the propylene glycol vehicle, and results reverse on stopping.
RU-58841: animal studies, then silence
RU-58841's evidence base is real but narrow and old. De Brouwer and colleagues grafted scalp from balding men onto testosterone-conditioned nude mice and treated the grafts topically for six months; RU-58841 grafts showed more follicles entering a second cycle and significantly higher linear hair growth rates than ethanol controls [6]. Pan and colleagues reported that topical RU-58841 produced a potent increase in hair density, thickness and length in the stump-tailed macaque model, the classic primate model of androgenetic alopecia, with no systemic effects detected [3]. That is the complete controlled record. There is no randomised human trial, no dose-ranging study, no long-term safety data. We cover what the animal studies can and cannot tell you in Does RU58841 work?
Why they are not interchangeable
A growth stimulant and an antiandrogen address different parts of the problem. Minoxidil can push a follicle to grow for a while, but if DHT keeps signalling, the underlying miniaturisation continues. An AR antagonist can, in principle, remove the signal but offers no direct push toward growth. That is why the licensed standard of care pairs minoxidil with a 5-alpha-reductase inhibitor, and why forum users have long speculated about pairing it with a topical AR antagonist instead. Whether a research compound should be used for that purpose is a question for a clinician, not a supplier, and anyone considering finasteride or dutasteride should take that to a prescriber.
The one piece of controlled combination data in this niche does not involve RU-58841 at all. In May 2025 Kintor reported an open-label, randomised observational study of 75 Chinese men in which pyrilutamide (KX-826) 0.5% plus 5% minoxidil produced about 10 hairs/cm² more than minoxidil alone at 24 weeks [7]. It is small, unblinded and company-reported, but it is the first controlled signal that adding a topical AR antagonist to minoxidil does something measurable. Pyrilutamide and RU-58841 are different molecules, so the result cannot be transferred. See RU-58841 vs pyrilutamide.
Side effects and safety
Minoxidil's adverse-effect profile is documented in trial data: scalp irritation and pruritus, an initial shed in some users, unwanted facial hair in some women, and rare cardiovascular effects at high systemic exposure. RU-58841's profile is not documented at all in humans. The 1994 rat pharmacokinetic work from Roussel-Uclaf found the parent compound cleared quickly and formed little of its slow-clearing active metabolite, which the authors linked to its lack of systemic antiandrogen effect in animals [8]. That is reassuring in a rat. It is not a human safety study. We go through the systemic question properly in RU58841 half-life and systemic absorption and the full side-effect picture in RU58841 side effects.
Legal and practical status in the UK
Minoxidil 2% and 5% are licensed pharmacy medicines, sold over the counter with a product licence, a patient leaflet and MHRA oversight. RU-58841 has none of those. It is not a controlled substance, but it is also not a medicine, and it cannot legally be sold or advertised for hair loss. It is supplied as a research chemical for laboratory use. That is the only capacity in which Norwood Labs sells it, and it is why none of our material carries usage directions. For the legal detail see Is RU-58841 legal in the UK?
An honest bottom line
If you want the compound with evidence, it is minoxidil, and that is not close. If you are researching androgen receptor antagonism at the follicle, RU-58841 is the most studied unlicensed molecule in that class, with a mechanism that is well characterised and an outcome record that stops at primates. Those are different things, and a comparison that pretends otherwise is selling, not informing.
References
- Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150(2):186-194. PMID 14996087
- Battmann T, Bonfils A, Branche C, et al. RU 58841, a new specific topical antiandrogen: a candidate of choice for the treatment of acne, androgenetic alopecia and hirsutism. J Steroid Biochem Mol Biol. 1994;48(1):55-60. PMID 8136306
- Pan HJ, Wilding G, Uno H, et al. Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques. Endocrine. 1998;9(1):39-43. PMID 9798729
- Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377-385. PMID 12196747
- Gupta AK, Venkataraman M, Talukder M, Bamimore MA. Relative efficacy of minoxidil and the 5-α reductase inhibitors in androgenetic alopecia treatment of male patients: a network meta-analysis. JAMA Dermatol. 2022;158(3):266-274. PMC8811710
- De Brouwer B, Tételin C, Leroy T, Bonfils A, Van Neste D. A controlled study of the effects of RU58841, a non-steroidal antiandrogen, on human hair production by balding scalp grafts maintained on testosterone-conditioned nude mice. Br J Dermatol. 1997;137(5):699-702. PMID 9415227
- Kintor Pharmaceutical. Superior efficacy of clinical observational study in KX-826 in combination with minoxidil for the treatment of male adults with AGA in China over minoxidil monotherapy. Company announcement, 2 May 2025. kintor.com.cn
- Cousty-Berlin D, Bergaud B, Bruyant MC, Battmann T, Branche C, Philibert D. Preliminary pharmacokinetics and metabolism of novel non-steroidal antiandrogens in the rat: relation of their systemic activity to the formation of a common metabolite. J Steroid Biochem Mol Biol. 1994;51(1-2):47-55. PMID 7947350